BridgeBio Pharma Inc (BBIO): Next-Year EPS Estimate 101.88%
As of 2026-08-25, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 101.88%. Featured in our EPS revision report on 2026-07-09.
On 2026-08-12, analyst consensus for BBIO's next-year EPS growth shifted from 106.69% to 101.88% — a negative change of 4.81 percentage points. The revised estimate has been sustained across 12 subsequent trading sessions. Current-year growth is projected at 29.32%.
What's Driving This
The primary structural driver is the August 3 analyst upgrade to next-year EPS growth from 122.64% to 125.98%. That revision was reinforced by headlines that AstraZeneca and Ionis’ heart drug failed a key trial, which investors saw as improving BridgeBio’s competitive position; BofA called the failure a big surprise. BBIO surged 16% on that news,
Generated 2026-08-10 from news as of 2026-08-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 101.88%
- EPS growth this year
- 29.32%
- EPS next quarter (est)
- -$0.62
- Last price
- $80.40
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 101.88% | 29.32% | -$0.62 | $80.40 |
| 2026-08-24 | 101.88% | 29.32% | -$0.62 | $81.07 |
| 2026-08-23 | 101.88% | 29.32% | -$0.62 | $81.50 |
| 2026-08-21 | 101.88% | 29.32% | -$0.62 | $81.50 |
| 2026-08-20 | 101.88% | 29.32% | -$0.62 | $82.94 |
| 2026-08-19 | 101.88% | 29.32% | -$0.62 | $83.95 |
| 2026-08-18 | 101.88% | 29.32% | -$0.62 | $82.98 |
| 2026-08-17 | 101.88% | 29.32% | -$0.62 | $79.89 |
| 2026-08-16 | 101.88% | 29.32% | -$0.62 | $79.86 |
| 2026-08-14 | 101.88% | 29.32% | -$0.62 | $79.86 |
| 2026-08-13 | 101.88% | 29.32% | -$0.62 | $81.21 |
| 2026-08-12 | 101.88% | 29.32% | -$0.62 | $83.84 |
| 2026-08-11 | 106.69% | 30.96% | -$0.60 | $83.70 |
| 2026-08-10 | 125.98% | 41.04% | -$0.49 | $84.67 |
| 2026-08-09 | 125.98% | 41.04% | -$0.58 | $84.48 |
| 2026-08-07 | 125.98% | 41.04% | -$0.58 | $84.48 |
| 2026-08-06 | 125.98% | 41.04% | -$0.58 | $82.80 |
| 2026-08-05 | 125.98% | 41.04% | -$0.58 | $81.99 |
| 2026-08-04 | 125.98% | 41.04% | -$0.58 | $82.07 |
| 2026-08-03 | 125.98% | 41.04% | -$0.58 | $79.96 |
| 2026-08-02 | 122.64% | 40.44% | -$0.58 | $80.09 |
| 2026-07-31 | 122.64% | 40.44% | -$0.58 | $80.09 |
| 2026-07-30 | 122.64% | 40.44% | -$0.58 | $82.14 |
| 2026-07-29 | 122.64% | 40.44% | -$0.58 | $83.54 |
| 2026-07-28 | 122.64% | 40.44% | -$0.58 | $85.55 |
| 2026-07-27 | 122.64% | 40.44% | -$0.58 | $84.12 |
| 2026-07-26 | 122.64% | 40.44% | -$0.58 | $84.02 |
| 2026-07-24 | 122.64% | 40.44% | -$0.58 | $84.02 |
| 2026-07-23 | 122.64% | 40.44% | -$0.58 | $82.93 |
| 2026-07-22 | 123.45% | 40.68% | -$0.58 | $82.66 |
Reports Featuring BBIO
Recent News
- BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ETGlobeNewswire
- Yext, Mission Produce, and 3 More Stocks See Action From Activist InvestorsBarrons.com
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?Trefis
- Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?Trefis
- BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal BofA Calls Failure A Big SurpriseStocktwits
- AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key TrialThe Wall Street Journal
- Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To JumpInvestor's Business Daily
- AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.Barrons.com
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is BridgeBio Pharma Inc's next-year EPS growth estimate?▾
As of 2026-08-25, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 101.88%, based on analyst consensus.
When was the latest EPS estimate revision for BBIO?▾
The most recent revision occurred on 2026-08-12, when analysts adjusted the next-year EPS growth estimate from 106.69% to 101.88%.
What sector and industry does BridgeBio Pharma Inc belong to?▾
BridgeBio Pharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. BridgeBio Pharma Inc (BBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.